« Big Ministry Meeting: Why are India Pharma Groups Selling to MNCs? | Main | Comparative Value Proof - New Drugs, Biosimilars & Generics »
Amgen received news today that its drug denosumab, branded Prolia, received its first approval in the EU for the treatment of osteoporosis in women and bone loss in men following hormonal therapy for prostate cancer.
EU approvals for Amgen’s osteo drug Prolia - Pharma Letter.
Prolia has been viewed as an important drug to the company's future earnings and this must be viewed as good news back in California.
Posted by Bruce Lehr May 28th 2010.
| | |
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b013482645f7a970c
Listed below are links to weblogs that reference EU approvals for Amgen’s drug Prolia (denosumab):
You can follow this conversation by subscribing to the comment feed for this post.
The comments to this entry are closed.
The FDA follows suit and give Prolia early approval. Go Dmab!
http://blogs.forbes.com/sciencebiz/2010/06/amgen-bone-drug-gets-fda-nod/
Posted by: bigredbruce | 06/01/2010 at 06:14 PM